Together with you, we transform phototherapy into a wearable, mobile solution, allowing parents to comfort their baby at home or in the hospital.
Our patented technology is designed for safe and easy wearable phototherapy. It includes the Remote Care Service. In co-creation with your hospital, we develop the Jaundice Care Path to ensure Zero Separation.
Together with you, we transform phototherapy into a wearable, mobile solution, allowing parents to comfort their baby at home or in the hospital.
Our patented technology is designed for safe and easy wearable phototherapy. It includes the Remote Care Service. In co-creation with your hospital, we develop the jaundice Care Path for Zero Separation.
Via the Zero Separation Care Path our technology integrates seamlessly into hospitals, offering the only wearable, mobile phototherapy device that enables full parental contact during treatment. Unlike traditional methods that isolate newborns in incubators, our solution supports kangaroo care, reducing stress and improving bonding.
By implementing our technology and Zero Separation Care Path, hospitals can:
For eligible newborns, our technology provides a clinically evaluated, cost-effective alternative to hospitalization. Parents receive a small phototherapy device supported by an easy-to-use Remote Care Service that offers outpatient monitoring and step-by-step guidance. With the Zero Separation Care Path, home care is easily integrated into your hospital.
By shifting care to the home setting:
Via the Zero Sepatation Care Path our technology integrates seamlessly into hospitals, offering the only wearable, mobile phototherapy device that enables full parental contact during treatment. Unlike traditional methods that isolate newborns in incubators, our solution supports kangaroo care, reducing stress and improving bonding.
By implementing our technology and Zero Separation Care Path, hospitals can:
For eligible newborns, our technology provides a clinically evaluated, cost-effective alternative to hospitalization. Parents receive a small phototherapy device supported by an easy-to-use Remote Care Service that offers outpatient monitoring and step-by-step guidance. With the Zero Separation Care Path, home care is easily integrated into your hospital.
By shifting care to the home setting:
Our patented technology is designed for safe and easy wearable phototherapy. It includes the Remote Care Service. We co-create with your hospital, to implement your jaundice Care Path for Zero Separation.
At the core of our Care Path is our patented technology Jauni Wearable Phototherapy, designed for both hospital and home use. This ultra-light, mobile device replaces bulky, isolating treatment methods with an effective solution: easy to use, comfortable to wear, and uninterrupted clinically evaluated therapy. The device is first of its kind. Babies stay secure in their parents' embrace while receiving clinically evaluated therapy. This not only reduces stress for newborns and parents but also helps hospitals save on nursing hours and incubator stays.
The Remote Care Service helps parents care for their newborn during treatment by providing information and remote monitoring. Via the Remote Care App, parents can access pre-approved information and log key health indicators. Through their own computer applicaiton, healthcare staff monitor these health indicators remotely—ensuring safe, supported home-based jaundice care.
We don’t just offer a device—we help hospitals unburden and implement the jaundice Care Path for Zero Separation. The Care Path is a blue print for implementing Zero Separation jaundice care at your hospital, developed from bilihome's experience. Our team works closely with your hospital to align stakeholders, optimize workflows, and tailor care processes to fit your hospital’s needs. This way the adoption of patient-centered jaundice care is accelerated and hospitals are unburdend. Together we create your Care Path, based on our blue print.
By choosing bilihome, hospitals can make use of our Care Path co-creation strategy, making adoption smoother, faster, and more effective. Our goal is to unburden you, to ensure a fast implementation.
At the core of our Care Path is our patented technology Jauni Wearable Phototherapy, designed for both hospital and home use. This ultra-light, mobile device replaces bulky, isolating treatment methods with an effective solution: easy to use, comfortable to wear, and uninterrupted clinically evaluated therapy. The device is first of its kind. Babies stay secure in their parents' embrace while receiving clinically evaluated therapy. This not only reduces stress for newborns and parents but also helps hospitals save on nursing hours and incubator stays.
The Remote Care Service helps parents care for their newborn during treatment through information and remote monitoring. Via the Remote Care App, parents can access pre-approved information and log key health indicators. Through their own computer applicaiton, healthcare staff monitor these health indicators remotely—ensuring safe, supported home-based jaundice care.
We don’t just offer a device—we help hospitals unburden and implement the jaundice Care Path for Zero Separation. The Care Path is a blue print for implementing Zero Separation jaundice care at your hospital, developed from bilihome's experience. Our team works closely with your hospital to align stakeholders, optimize workflows, and tailor care processes to fit your hospital’s needs. This way the adoption of patient-centered jaundice care is accelerated and hospitals are unburdend. Together we create your Care Path, based on our blue print.
By choosing bilihome, hospitals can make use of our Care Path co-creation strategy, making adoption smoother, faster, and more effective. Our goal is to unburden you, to ensure a fast implementation.
Find studies on kangaroo care and jaundice, home jaundice therapy and the benefits of home therapy at the bottom of the page.
Find studies on kangaroo care and jaundice, home jaundice therapy and the benefits of home therapy at the bottom of the page.
Bilihome isn’t just about phototherapy—we are redefining neonatal care. Our end-to-end solution makes it easy for hospitals to implement zero-separation jaundice treatment, leading to:
Join the movement toward Zero-Separation Care. Let’s give newborns the best possible start in life—together.
Laleh Goudarzvand, Akram Dabirian, Manizheh Nourian, Hadi Jafarianesh & Mehdi Ranjbaran (2017): Comparison of conventional phototherapy and phototherapy along with Kangaroo mother care on cutaneous bilirubin of neonates with physiological jaundice, The Journal of Maternal-Fetal & Neonatal Medicine
Razie lori Kenari (MSC), Parvin Aziznejadroshan (PhD), Mohsen Haghshenas Mojaveri (MD), Karimollah Hajian-Tilaki (PhD (2020): Comparing the effect of kangaroo mother care and field massage on serum bilirubin level of term neonates with hyperbilirubinemia under phototherapy in the neonatal ward, Caspian J Intern Med 2020; 11(1):34-40.
Xiang Huang, Meiling Chen , Rongrong Fu, Wei He, Yujing He, Haojie Shentu and Suping Zhu (2023): Efficacy of kangaroo mother care combined with neonatal phototherapy in newborns with non-pathological jaundice: A meta-analysis, Frontiers in Pediatrics.
Miriam Pettersson, Mats Eriksson, Andreas Odlind, Andreas Ohlin (2022): Home phototherapy of term neonates improves parental bonding and stress: Findings from a randomised controlled trial, Acta Paediatrica. 2022; 111: 760–766.
DOI: 10.1111/apa.16231
Mona Noureldein, Grace Mupanemunda, Helen McDermott,
Katy Pettit, Richard Mupanemunda (2021): Home phototherapy for neonatal jaundice in the UK: a single-centre retrospective service evaluation and parental survey, BMJ Paediatrics Open 2021;5:e001027
Cnossen, M. C., Spaan, J., Fleischmann, M. S., van der Geest, B. A., Ista, E., Hulzebos, C. V., ... & van der Vliet–Torij, H. W. H. (2024): Home phototherapy for neonatal hyperbilirubinemia: current practices and attitudes, Pediatric Research (2024): 1-7
Miriam Pettersson, Linda Ryen, Mats Eriksson & Andreas Ohlin (2023): The cost-effectiveness of home phototherapy for hyperbilirubinemia in neonates: results from a randomized controlled trial, Acta Paediatrica. 2022; 111: 760–766.
Bilihome B.V.
Van Siburgstraat 34
3863 HW Nijkerk
The Netherlands
KVK: 75075938
VAT: NL860132109B01
Copyright © 2025 bilihome B.V.
Bilihome B.V.
Van Siburgstraat 34
3863 HW Nijkerk
The Netherlands
KVK: 75075938
VAT: NL860132109B01
Copyright © 2025 bilihome B.V.